United States · Platforms & data · Yahoo Finance

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

Published by Yahoo Finance · United States 9 h ago

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

The Motley Fool

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

TheStreet

Vanguard flags a hidden AI risk in your value fund

Stocktwits

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

Share

Also worth reading

2 Quantum Computing Stocks That Could Help Make You a Fortune

Audi defends decision to stand by Trump on $4 billion US factory in Georgia

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Vanguard flags a hidden AI risk in your value fund

AI Tokens Post A Mixed Bag As Grayscale Spotlights Three Projects Beyond TAO, NEAR And WLD